DGAP-News

Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal

DGAP-News: Keryx Biopharmaceuticals, Inc. /
Keryx Biopharmaceuticals Strengthens Leadership Team With Key
Additions in Sales, Corporate Development and Legal

15.04.2014 / 14:30

---------------------------------------------------------------------

NEW YORK, 2014-04-15 14:30 CEST (GLOBE NEWSWIRE) --
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company
focused on the acquisition, development and commercialization of pharmaceutical
products for the treatment of renal disease, today announced the appointment of
three key executives in high priority strategic roles integral to the
preparation for the potential Zerenex(tm) (ferric citrate coordination complex)
product launch. The Company's New Drug Application for Zerenex(tm), an oral,
ferric iron-based compound, is currently under review by the FDA with an
assigned Prescription Drug User Fee Act (PDUFA) target goal date of June 7,
2014.

Brian R. Adams has been appointed Vice President, General Counsel. Mr. Adams
comes to the Company with significant legal and business management experience
within the pharmaceutical industry. Mr. Adams joins the Company from Algeta
ASA, where he served as its General Counsel, with oversight of all global legal
matters, corporate governance, alliance management and strategic transactions,
including the highly successful launch of of Xofigo(r) in prostate cancer,
resulting in a $2.9B acquisition bid for Algeta by Bayer AG. Prior to joining
Algeta in 2012, Mr. Adams spent six years as an in-house counsel for Genzyme
Corporation and AVEO Oncology. Throughout his career, Mr. Adams has provided
domestic and international legal support for product development, operations,
commercialization, securities, healthcare compliance and licensing/M&A
transactions. Prior to joining Genzyme, Mr. Adams practiced in the Boston
office of Bingham McCutchen LLP, where he advised private equity sponsors,
biotech and other emerging technology companies on a broad range of corporate
matters and financing transactions. Mr. Adams received a BA from Harvard
University and a law degree (JD) from the Catholic University of America's
Columbus School of Law.

Thomas M. Edwards has been appointed Vice President, US Sales, and will focus
on building and leading the US Sales and Sales Training organization. With a
pharmaceutical sales career spanning more than 22 years, Mr. Edwards brings a
strong background in sales management, training and leadership development,
with extensive product launch experience across multiple specialty indications.
Over the course of his career, Mr. Edwards has built and led high-performing
teams that have contributed to the overall success of specialty pharmaceutical